JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Travis, D. M.
Right arrow Articles by Maren, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Travis, D. M.
Right arrow Articles by Maren, T. H.
Journal of Pharmacology And Experimental Therapeutics, Vol. 151, Issue 3, 464-481, 1966
Copyright © 1966 by American Society for Pharmacology and Experimental Therapeutics


RESPIRATION DURING CHRONIC INHIBITION OF RENAL CARBONIC ANHYDRASE: FURTHER OBSERVATIONS ON PHARMACOLOGY OF 2-BENZENESULFONAMIDO-1,3,4-THIADIAZOLE-5-SULFONAMIDE (CL 11,366), ACETAZOLAMIDE AND METHAZOLAMIDE

David M. Travis 1, Christine Wiley 1, and Thomas H. Maren 1

1 Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, Florida

Selective renal carbonic anhydrase inhibition with full renal HCO3- response may be obtained without respiratory effect of erythrocytic enzyme inhibition during chronic administration of 2-benzenesulfonamido-1,3,4-thiadiazole -5-sulfonamide (CL 11,366) in unanesthetized dogs by appropriate choice of dose and interval. As little as 0.5 mg/kg i.m. gives maximal rates of renal HCO3- loss, and administration every 4 hr approaches maximally sustained plasma HCO3- depletion. As much as 10 mg/kg p.o. every 12 hr fails to bring about respiratory changes characteristic of erythrocytic inhibition. Studies of distribution of CL 11,366 show it to be concentrated in kidney and lung, where it is apparently secreted, and to be low in muscle and brain, from which it is largely excluded because of high plasma binding and poor diffusibility. Exclusion of physiologically effective concentration from erythrocytes is possible because the composite of chemical and pharmacologic factors keep free drug in the red cells at a lower level than the unbound plasma inhibitor concentration, which is small at maximum renal doses.

Accepted on September 24, 1965







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1966 by the American Society for Pharmacology and Experimental Therapeutics.